16 September 2026 editorial review · Trial
Tirzepatide and gastric emptying in adults with T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: New 18-person Phase 1 T1D study uses acetaminophen pharmacokinetics to assess gastric emptying; not long-term HbA1c efficacy. Not yet recruiting; dates are estimates.
Registry: NCT07803744; NOT_YET_RECRUITING; updated 2026-09-04; enrollment 18 (ESTIMATED); results not posted.
Endpoint comparison: Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen (Predose on Day 1 through 36 hours post dose); PK: Area Under the Concentration Versus Time Curve from Time Zero to Time t (AUC0-tlast) of Acetaminophen (Predose on Day 1 through 36 hours post dose); PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen (Predose on Day 1 through 36 hours post dose).
Sources for this record: A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity (NCT07803744) (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.